{
    "ids": [
        [
            "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf-Effect of Termination-52",
            "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf-Termination-51",
            "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf-Termination Fees\u037e Expense Reimbursements-53",
            "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf-Termination of the Merger Agreement-7",
            "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf-Severability-56",
            "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf-Remedies-57",
            "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf-Entire Agreement\u037e Third-Party Beneficiaries-55",
            "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf-Termination Fees-8",
            "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf-Conditions to Obligations of the Company-50",
            "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf-Conditions to Obligations of Each Party-49"
        ],
        [
            "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf-Indemnification-45",
            "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf-Annex C-12",
            "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf-Taxes-34",
            "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf-Solicitation of Proxies-11",
            "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf-Annex D-Opinion of Guggenheim Securities, LLC-28",
            "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf-Annex C-Opinion of Goldman Sachs & Co. LLC-27"
        ],
        [
            "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf-Data Protection and Privacy-37",
            "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf-Access to Information-43",
            "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf-Intellectual Property\u037e Software-36"
        ]
    ],
    "distances": [
        [
            0.3236096203327179,
            0.34547871351242065,
            0.3829956352710724,
            0.3858928680419922,
            0.3904575705528259,
            0.3935306966304779,
            0.40322986245155334,
            0.4081331193447113,
            0.4155005216598511,
            0.4309394359588623
        ],
        [
            0.31852519512176514,
            0.4702315628528595,
            0.4786145091056824,
            0.4809986352920532,
            0.5005004405975342,
            0.5061256289482117
        ],
        [
            0.38827982544898987,
            0.42461028695106506,
            0.4617522656917572
        ]
    ],
    "metadatas": [
        [
            {
                "Document": "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf",
                "End Page": 168,
                "Keyword": "Termination",
                "Section Header": "Effect of Termination",
                "Start Page": 168
            },
            {
                "Document": "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf",
                "End Page": 168,
                "Keyword": "Termination",
                "Section Header": "Termination",
                "Start Page": 166
            },
            {
                "Document": "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf",
                "End Page": 169,
                "Keyword": "Termination",
                "Section Header": "Termination Fees\u037e Expense Reimbursements",
                "Start Page": 168
            },
            {
                "Document": "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf",
                "End Page": 18,
                "Keyword": "Termination",
                "Section Header": "Termination of the Merger Agreement",
                "Start Page": 17
            },
            {
                "Document": "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf",
                "End Page": 172,
                "Keyword": "Termination",
                "Section Header": "Severability",
                "Start Page": 172
            },
            {
                "Document": "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf",
                "End Page": 173,
                "Keyword": "Termination",
                "Section Header": "Remedies",
                "Start Page": 173
            },
            {
                "Document": "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf",
                "End Page": 172,
                "Keyword": "Termination",
                "Section Header": "Entire Agreement\u037e Third-Party Beneficiaries",
                "Start Page": 171
            },
            {
                "Document": "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf",
                "End Page": 18,
                "Keyword": "Termination",
                "Section Header": "Termination Fees",
                "Start Page": 18
            },
            {
                "Document": "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf",
                "End Page": 166,
                "Keyword": "Termination",
                "Section Header": "Conditions to Obligations of the Company",
                "Start Page": 166
            },
            {
                "Document": "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf",
                "End Page": 165,
                "Keyword": "Termination",
                "Section Header": "Conditions to Obligations of Each Party",
                "Start Page": 165
            }
        ],
        [
            {
                "Document": "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf",
                "End Page": 159,
                "Keyword": "Indemnification",
                "Section Header": "Indemnification",
                "Start Page": 158
            },
            {
                "Document": "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf",
                "End Page": 203,
                "Keyword": "Indemnification",
                "Section Header": "Annex C",
                "Start Page": 203
            },
            {
                "Document": "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf",
                "End Page": 137,
                "Keyword": "Indemnification",
                "Section Header": "Taxes",
                "Start Page": 137
            },
            {
                "Document": "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf",
                "End Page": 33,
                "Keyword": "Indemnification",
                "Section Header": "Solicitation of Proxies",
                "Start Page": 32
            },
            {
                "Document": "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf",
                "End Page": 209,
                "Keyword": "Indemnification",
                "Section Header": "Annex D-Opinion of Guggenheim Securities, LLC",
                "Start Page": 205
            },
            {
                "Document": "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf",
                "End Page": 205,
                "Keyword": "Indemnification",
                "Section Header": "Annex C-Opinion of Goldman Sachs & Co. LLC",
                "Start Page": 203
            }
        ],
        [
            {
                "Document": "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf",
                "End Page": 142,
                "Keyword": "Confidentiality",
                "Section Header": "Data Protection and Privacy",
                "Start Page": 141
            },
            {
                "Document": "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf",
                "End Page": 155,
                "Keyword": "Confidentiality",
                "Section Header": "Access to Information",
                "Start Page": 155
            },
            {
                "Document": "MAGELLAN HEALTH INC_20210219_DEFM14A_19054835_4126183.Pdf",
                "End Page": 141,
                "Keyword": "Confidentiality",
                "Section Header": "Intellectual Property\u037e Software",
                "Start Page": 139
            }
        ]
    ],
    "documents": [
        [
            "Section 7.2 Effect of Termination. This Agreement may be terminated only under Section 7.1. In order to terminate\nthis Agreement under Section 7.1, the Party desiring to terminate this Agreement shall give written notice of such\ntermination to the other Parties under Section 8.4, specifying the subsection of Section 7.1 under which such\ntermination is effected. If this Agreement is terminated under Section 7.1, this Agreement shall immediately become\nvoid and of no effect, and no Party (or their respective Representatives) shall have any further Liability, whether\narising before, at or after such termination, that may be based on this Agreement, arising out of this Agreement or\nrelating hereto or the negotiation, execution, performance or subject matter hereof, except that (a) Section 5.9(d), this\nSection 7.2, Section 7.3 and Article VIII, and the Parties\u2019 Liabilities thereunder, shall survive such termination and\nremain in full force and effect in accordance with their terms and (b) no such termination shall relieve any Party from\nLiability for any Willful Breach occurring prior to such termination. No termination hereof shall affect the Parties\u2019\nrespective obligations under the Confidentiality Agreement, the Clean Room Agreement and the Synergies Clean\nTeam Agreement, all of which obligations shall survive any termination hereof under their terms (notwithstanding\nanything in Section 8.6 to the contrary).\nSection 7.3",
            "Section 7.1 Termination.\n(a) Termination by Mutual Agreement. Parent and the Company shall have the right to terminate this\nAgreement at any time prior to the Effective Time by mutual written agreement, whether before or after\nobtainment of the Company Stockholder Approval.\n(b) Termination by Either Parent or the Company. Each of Parent and the Company shall have the right to\nterminate this Agreement at any time prior to the Effective Time, whether before or after obtainment of the\nCompany Stockholder Approval, if:\n(i) the Closing has not occurred prior to 5:00 p.m. on October 4, 2021 (the \u201cOutside Date\u201d)\u037e provided,\nhowever, that, if, as of 5:00 p.m. on the Outside Date, all of the conditions in Article VI have been satisfied\nor duly waived by all Parties entitled to the benefit thereof (except for (1) the conditions in Section 6.1(b)\n(but only if each applicable Legal Restraint relates to the HSR Clearance or a Required Consent) and\nSection 6.1(c)) and (2) any condition that by its nature is to be satisfied at the Closing (provided that such\ncondition would be capable of being satisfied if the Closing Date were the Outside Date), the Outside Date\nshall be extended to January 4, 2022\u037e provided, further, however, that the right to terminate this Agreement\nunder this Section 7.1(b)(i) shall not be available to a Party if the failure of the Closing to have occurred\nprior to 5:00 p.m. on the Outside Date (as it may be extended under this Section 7.1(b)(i)) was proximately\ncaused by such Party\u2019s breach of, or such Party\u2019s failure to perform or comply with, in any material respect,\nany of its covenants or agreements hereunder\u037e\nA-47TABLE OF CONTENTS\n(ii)\u2003a Legal Restraint shall be in effect that has become final and nonappealable\u037e provided, however, that\nthe right to terminate this Agreement under this Section 7.1(b)(ii) shall not be available to a Party if the\nexistence of such Legal Restraint was proximately caused by such Party\u2019s breach of, or failure to perform or\ncomply with, in any material respect, any of its covenants or agreements hereunder\u037e or\n(iii)\u2003the Company Stockholder Approval is not obtained at the Company Stockholders Meeting or at any\nadjournment or postponement thereof at which a vote on the adoption hereof was taken.\n(c)\u2003Termination by Parent. Parent shall have the right to terminate this Agreement at any time prior to the\nEffective Time if:\n(i)\u2003the Company Board or a committee thereof makes a Company Change of Recommendation (regardless\nof whether such Company Change of Recommendation was permitted under Section 5.4(e) or Section\n5.4(f))\u037e provided, however, that Parent shall not have the right to terminate this Agreement under this\nSection 7.1(c)(i) after the Company Stockholder Approval is obtained\u037e\n(ii)\u2003(1) the Company has committed a Willful Breach of Section 5.4 and (2) such Willful Breach cannot be\ncured by the date of the Company Stockholders Meeting or, if capable of being cured, is not cured within\nten (10) Business Days after written notice of such breach to the Company\u037e provided, however, that, from\nand after obtainment of the Company Stockholder approval, Parent shall not have the right to terminate this\nAgreement under this Section 7.1(c)(ii) for any such Willful Breach occurring prior to such obtainment\u037e or\n(iii)\u2003the Company breaches, or fails to perform or comply with, any of its covenants or agreements\nhereunder, or any of the Company\u2019s representations or warranties hereunder fails to be accurate, which\nfailure (1) would give rise to the failure of a condition in Section 6.2(a) or Section 6.2(b), as applicable, to be\nsatisfied and (2) is not reasonably capable of being cured by the Company or, if reasonably capable of\nbeing cured by the Company, is not cured by the Company prior to the earlier of (a) thirty (30) days after\nParent delivers written notice of such failure to the Company and (b) the Outside Date (as it may be\nextended under Section 7.1(b)(i))\u037e provided, however, that Parent shall not have the right to terminate this\nAgreement under this Section 7.1(c)(iii) if Parent or Merger Sub breach, or fail to perform or comply with, in\nany material respect, any of their respective covenants or agreements hereunder, or any of Parent\u2019s or\nMerger Sub\u2019s respective representations or warranties hereunder fails to be accurate in any material\nrespect, which failure would proximately give rise to the failure of a condition in Section 6.3(a) or Section\n6.3(b), as applicable.\n(d)\u2003Termination by the Company. The Company shall have the right to terminate this Agreement at any time\nprior to the Effective Time if:\n(i)\u2003(1) the Company Board has authorized the Company to terminate this Agreement under this Section\n7.1(d)(i) in response to a Superior Acquisition Proposal under Section 5.4(e), (2) Parent is not then entitled\nto terminate this Agreement under Section 7.1(c)(ii) and (3) concurrently with such termination, a written\ndefinitive agreement providing for the consummation of the transactions contemplated by such Superior\nAcquisition Proposal is duly executed and delivered by the Company, the Person making such Superior\nAcquisition Proposal and all other parties thereto\u037e provided, however, that the Company shall not be\nentitled to terminate this Agreement under this Section 7.1(d)(i), and no such purported termination shall\nhave any effect, unless, prior to or concurrently with such termination, the Company pays Parent the\nTermination Fee under Section 7.3(a)\u037e or\n(ii)\u2003any of Parent or Merger Sub breach, or fail to perform or comply with, any of their respective\ncovenants or agreements hereunder, or any of Parent\u2019s or Merger Sub\u2019s respective representations or\nwarranties hereunder fails to be accurate, which failure (1) would give rise to the failure of a condition in\nSection 6.3(a) or Section 6.3(b), as applicable, to be satisfied and (2) is not reasonably capable of being\ncured by Parent or Merger Sub, as applicable, or, if reasonably capable of being cured by Parent or Merger\nSub, as applicable, is not cured by Parent or Merger Sub, as applicable, prior to the earlier of (a) thirty (30)\ndays after the Company delivers written notice of such failure to Parent and (b) the Outside Date (as it may\nbe extended under Section 7.1(b)(i))\u037e provided, however, that the Company shall not have the right to\nterminate this Agreement under this\nA-48\nTABLE OF CONTENTS\nSection 7.1(d)(ii) if the Company breaches, or fails to perform or comply with, in any material respect, any of\nits covenants or agreements hereunder, or any of the Company\u2019s representations or warranties hereunder\nfails to be accurate in any material respect, which failure would proximately give rise to the failure of a\ncondition in Section 6.2(a) or Section 6.2(b), as applicable.\nSection 7.2",
            "Section 7.3 Termination Fees\u037e Expense Reimbursements.\n(a) Termination Fees.\n(i) Termination Fee. If (1)(A) Parent terminates this Agreement under Section 7.1(c)(i) or Section 7.1(c)(ii)\nor (B) the Company terminates this Agreement under Section 7.1(d)(i) or (2) Parent or the Company\nterminates this Agreement under Section 7.1(b)(iii) and, at the time of such termination, Parent would have\nbeen entitled to terminate this Agreement under Section 7.1(c)(i) or Section 7.1(c)(ii), the Company shall\npay to Parent a fee of $76,530,000 in cash (the \u201cTermination Fee\u201d), by wire transfer of immediately available\nfunds in accordance with wiring instructions delivered in writing to the Company by Parent, (A) no later\nthan two (2) Business Days after the date of such termination for a termination contemplated by the\nforegoing clauses (1)(A) and (2) or (B) prior to or concurrently with such termination for a termination\ncontemplated by the foregoing clause (1)(B).\n(ii) Tail Fee. The Company shall pay to Parent a fee in cash equal to the Termination Fee (the \u201cTail Fee\u201d\nand, together with the Termination Fee, the \u201cCompany Fees\u201d), if (1) Parent or the Company terminates this\nAgreement under Section 7.1(b)(iii) and, at the time of such termination, Parent would not have been\nentitled to terminate this Agreement under Section 7.1(c)(i) or Section 7.1(c)(ii), (2) prior to such\ntermination, but after the date hereof, a bona fide Alternative Acquisition Proposal is made to the Company\nor the Company Board or is made publicly known and (3) within twelve (12) months after the date of such\ntermination, the Company enters into a definitive Alternative Acquisition Agreement with respect to, or\nconsummates, any Alternative Acquisition Proposal (whether or not referred to in the foregoing clause\n(2))\u037e provided that, for purposes of this Section 7.3(a)(ii), the references to \u201c25%\u201d in the definition of\nAlternative Acquisition Proposal shall be deemed to be references to \u201c50%.\u201d If owed under this Section\n7.3(a)(ii), the Company shall pay to Parent the Tail Fee by wire transfer of immediately available funds in\naccordance with wiring instructions delivered in writing to the Company by Parent prior to or concurrently\nwith the execution of such Alternative Acquisition Agreement.\n(b) Other Agreements.\n(i) The covenants and agreements under this Section 7.3 are an integral part of the transactions\ncontemplated hereby, and without such covenants and agreements, the Parties would not have entered\ninto this Agreement. If the Company fails to pay promptly any Company Fee due under Section 7.3(a), as\napplicable, and in order to obtain such payment, the Parent commences an Action that results in a final,\nnon-appealable judgment against the Company for such Company Fee owed thereby under Section 7.3(a),\nas applicable, or any portion thereof, the Company shall reimburse Parent for its reasonable and\ndocumented out-of-pocket costs and expenses (including reasonable and documented\nA-49TABLE OF CONTENTS\nattorneys\u2019 fees) in connection with such Action, together with interest on such amount at the prime rate as\npublished in The Wall Street Journal in effect on the date such payment was required to be made through\nthe date such payment was actually received.\n(ii) Notwithstanding anything herein to the contrary (including Section 7.2), if this Agreement is\nterminated under circumstances in which the Company is required to pay a Company Fee, (1) payment by\nthe Company of such Company Fee, together with any costs and expenses owed by the Company under\nSection 7.3(b)(i), shall be Parent\u2019s sole and exclusive remedy (and that of Parent\u2019s stockholders, directors,\nofficers and Affiliates and Representatives (collectively with Parent, the \u201cParent Related Parties\u201d)) for any\nActions, Liabilities losses, damages, judgments, inquiries, fines and fees, costs and expenses, including\nattorneys\u2019 fees and disbursements, suffered or incurred by the Parent Related Parties that may be based on\nthis Agreement, arise out of this Agreement or relate hereto or the negotiation, execution, performance or\nsubject matter hereof, or the termination hereof or any matter forming the basis for such termination, or any\nbreach of, or failure to perform under, this Agreement or any certificate or other document delivered in\nconnection herewith or otherwise or in respect of any oral representation made or alleged to have been\nmade in connection herewith or therewith, (2) upon payment of such amount, together with any costs and\nexpenses owed by the Company under Section 7.3(b)(i), the Company, its Subsidiaries and Affiliates and\nany of their respective former, current or future general or limited partners, stockholders, controlling\nPersons, managers, members, directors, officers, employees, Affiliates, Representatives, agents or any their\nrespective assignees or successors (collectively, \u201cCompany Related Parties\u201d) shall have no further Liability\nthat may be based on this Agreement, arise out of this Agreement or relate hereto or the negotiation,\nexecution, performance or subject matter hereof, or the termination hereof or any matter forming the basis\nfor such termination, or any breach of, or failure to perform under, this Agreement or any certificate or other\ndocument delivered in connection herewith or otherwise or in respect of any oral representation made or\nalleged to have been made in connection herewith or therewith, (3) Parent shall not have, and expressly\nwaives and relinquishes on behalf of itself and the other Parent Related Parties, any other right, remedy or\nrecourse (whether in contract or in tort or otherwise, or whether at law (including at common law or by\nstatute) or in equity) that may be based on this Agreement, arise out of this Agreement or relate hereto or\nthe negotiation, execution, performance or subject matter hereof, or the termination hereof or any matter\nforming the basis for such termination, or any breach of, or failure to perform under, this Agreement or any\ncertificate or other document delivered in connection herewith or otherwise or in respect of any oral\nrepresentation made or alleged to have been made in connection herewith or therewith, and (4) the\nmaximum aggregate Liability of the Company Related Parties to Parent that may be based on this\nAgreement, arise out of this Agreement or relate hereto or the negotiation, execution, performance or\nsubject matter hereof, or the termination hereof or any matter forming the basis for such termination, or any\nbreach of, or failure to perform under, this Agreement or any certificate or other document delivered in\nconnection herewith or otherwise or in respect of any oral representation made or alleged to have been\nmade in connection herewith or therewith, shall not exceed such Company Fee, together with any costs\nand expenses owed by the Company under Section 7.3(b)(i), and the Parent Related Parties shall not seek\nto recover monetary damages in excess of such amount. Notwithstanding anything herein to the contrary\n(including Section 7.2), in no event shall the Company be required to pay to Parent more than one\nCompany Fee.\n(iii) The Parties acknowledge and hereby agree that the Termination Fee, if, as and when required\npursuant to this Section 7.3, shall not constitute a penalty but will be liquidated damages, in a reasonable\namount that will compensate Parent in the circumstances in which it is payable for the efforts and resources\nexpended and opportunities foregone while negotiating this Agreement and in reliance on this Agreement\nand on the expectation of the consummation of the Merger, which amount would otherwise be impossible\nto calculate with precision.\nARTICLE VIII\n \nMISCELLANEOUS\nSection 8.1",
            "Termination of the Merger Agreement (see page 82)\nThe Merger Agreement may be terminated at any time prior to the Effective Time by the mutual written agreement of\nCentene and Magellan. The Merger Agreement may also be terminated by either Centene or Magellan if:\n\u2022\nthe closing has not occurred by 5:00 p.m. on the outside date of October 4, 2021 (which we refer to as the\n\u201coutside date\u201d), except that, if, as of 5:00 p.m., New York City time, on the outside date, all of the closing\nconditions described under \u201cThe Merger Agreement-Conditions to the Merger\u201d have been satisfied or\nduly waived by all parties entitled to the benefit thereof except for (i) closing conditions regarding (a) the\nexistence of a legal restraint that relates to the HSR Act Clearance or a required consent, or (b) the HSR Act\nClearance, required filings or required consents having been made or obtained and (ii) any condition that\nby its nature is to be satisfied at the closing, the outside date will be extended to January 4, 2022, except\nthat a party may not terminate the Merger Agreement as described in this bullet point if the failure of the\nclosing to have occurred prior to 5:00 p.m. on the outside date (as it may be extended) was proximately\ncaused by such party\u2019s breach of, or such party\u2019s failure to perform or comply with, in any material respect,\nany of its covenants or agreements under the Merger Agreement\u037e\n\u2022\nany legal restraint is in effect that has become final and nonappealable, except that a party may not\nterminate the Merger Agreement as described in this bullet point if the existence of such legal restraint was\nproximately caused by such party\u2019s breach of, or such party\u2019s failure to perform or comply with, in any\nmaterial respect, any of its covenants or agreements under the Merger Agreement\u037e or\n\u2022\nthe Company stockholder approval is not obtained at the special meeting or at any adjournment or\npostponement thereof at which a vote on the adoption of the Merger Agreement is taken.\nCentene may also terminate the Merger Agreement at any time prior to the Effective Time if:\n\u2022\nprior to receipt of the Company stockholder approval, the Board has made a change of its recommendation\nto stockholders to adopt the Merger Agreement\u037e\n\u2022\nthe Company has committed a willful breach in any material respect of the no-solicitation provisions of the\nMerger Agreement in connection with an alternative acquisition proposal and such willful breach cannot\nbe cured by the date of the special meeting or, if capable of being cured, is not cured within ten (10)\nbusiness days after Centene delivers written notice of such breach to the Company\u037e or\n9TABLE OF CONTENTS\n\u2022\nthe Company breaches, or fails to perform or comply with, any of its covenants or agreements under the\nMerger Agreement, or any of the Company\u2019s representations or warranties under the Merger Agreement\nfails to be accurate, which failure (1) would give rise to the failure of a closing condition regarding the\naccuracy of the Company\u2019s representations and warranties or the Company\u2019s compliance with its\ncovenants and agreements and (2) is not reasonably capable of being cured by the Company or, if\nreasonably capable of being cured by the Company, is not cured by the Company prior to the earlier of (a)\nthirty (30) days after Centene delivers written notice of such failure to the Company and (b) the outside\ndate (as it may be extended as described above), except that Centene may not terminate the Merger\nAgreement as described in this bullet point if Centene or Merger Sub breach, or fail to perform or comply\nwith, in any material respect their respective covenants under the Merger Agreement or their respective\nrepresentations or warranties fail to be accurate in any material respect, which failure proximately gave rise\nto the failure of the closing conditions described herein.\nThe Company may also terminate the Merger Agreement at any time prior to the Effective Time if:\n\u2022\n(i) the Board has authorized the Company to terminate the Merger Agreement in response to a superior\nacquisition proposal in accordance with, and subject to the terms and conditions of, the provisions\ndescribed under \u201cThe Merger Agreement-Covenants and Agreements-No Solicitation-Change of\nRecommendation and Termination,\u201d (ii) Centene is not then entitled to terminate the Merger Agreement\nunder the second bullet set forth under Centene\u2019s termination rights above and (iii) concurrently with such\ntermination, a written definitive agreement providing for the consummation of the transactions\ncontemplated by such superior acquisition proposal is duly executed and delivered by the Company, the\nperson making such superior acquisition proposal and all other parties thereto, except that the Company\nmay not terminate the Merger Agreement as described in this bullet point, and no such purported\ntermination will have any effect, unless the Company pays Centene the applicable termination fee described\nin the section entitled \u201cThe Merger Agreement-",
            "Section 8.7 Severability. If any term, provision, covenant or restriction hereof is held by a court of competent\njurisdiction or other authority to be invalid, void, unenforceable or against its regulatory policy, the remainder of the\nterms, provisions, covenants and restrictions hereof shall remain in full force and effect and shall in no way be\naffected, impaired or invalidated. Upon such a determination, the Parties shall negotiate in good faith to modify this\nAgreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner in order\nthat the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible.\nSection 8.8",
            "Section 8.10 Remedies.\n(a) The Parties acknowledge and agree that irreparable damage would occur in the event that any provision\nhereof was not performed under their specific terms or were otherwise breached and that monetary damages,\neven if available, would not be an adequate remedy therefor. It is accordingly agreed that, at any time prior to the\ntermination hereof under Article VII, the Parties shall be entitled to an injunction or injunctions to prevent\nbreaches hereof and to enforce specifically the performance of terms and provisions hereof, without proof of\nactual damages (and each Party waives any requirement for the securing or posting of any bond in connection\nwith such remedy), this being in addition to any other remedy to which they are entitled at law or in equity. The\nParties further agree not to assert (i) that a remedy of specific enforcement is unenforceable, invalid, contrary to\nLaw or inequitable for any reason or (ii) that a remedy of monetary damages would provide an adequate remedy\nfor any such breach.\n(b) For the avoidance of doubt, in no event shall the exercise of a Party\u2019s right to seek specific performance\npursuant to this Section 8.10 reduce, restrict or otherwise limit such Party\u2019s right to terminate this Agreement\npursuant to Section 7.1 or pursue all applicable remedies at Law to the extent not limited hereby.\n(c) To the extent any Party brings any Action to enforce specifically the performance of the terms and\nprovisions of this Agreement, and such Action is pending on the Outside Date (as it may be extended under\nSection 7.1(b)(i)), then, without further action, the Outside Date (as it may be extended under Section 7.1(b)(i))\nshall automatically be extended until (i) the date that is five (5) Business Days following the dismissal,\nsettlement or entry of a final order with respect to such Action, or (ii) such other time period established by the\ncourt presiding over such Action.\nSection 8.11",
            "Section 8.6 Entire Agreement\u037e Third-Party Beneficiaries. This Agreement (including any exhibits hereto and the\nCompany Disclosure Schedule) and the Confidentiality Agreement (other than Paragraphs 4 and 5 (solely with\nrespect to Transaction Information (as defined therein)), thereof, each of which shall terminate (solely with respect to\nTransaction Information (as defined therein)) and be of no force or effect after the Parties\u2019 execution and delivery\nhereof\u037e provided for the avoidance of doubt, that if any Evaluation Material itself is or may be deemed to be\nTransaction Information, this parenthetical shall not apply to such information), the Clean Room Agreement and the\nSynergies Clean Team Agreement (a) are the entire agreement and supersede all prior agreements and\nunderstandings, both written and oral, among the Parties related to the subject matter hereof and thereof (although\nany provisions of the Confidentiality Agreement conflicting with this Agreement shall be governed by this\nAgreement) and (b) are not intended to confer any rights, benefits, remedies or Liabilities on any Person other than\nthe Parties and their respective successors and permitted assigns, except (i) as provided in Section 5.8(e), (ii), the\nright of the Company Stockholders to receive the Merger Consideration after the Closing in accordance herewith, (iii)\nthe right of the holders of Company Equity Awards to receive such consideration as provided for in Section 2.6 after\nthe Closing in accordance herewith, (iv) Section 7.3(b)(ii), which is intended to benefit and be enforceable by the\nCompany Related Parties and Parent Related Parties and (v) the Financing Sources are intended third-party\nbeneficiaries of Section 8.1, this Section 8.6, Section 8.9(b), Section 8.11 and Section 8.12 and such provisions shall be\nenforceable by each Financing Source.\nA-52TABLE OF CONTENTS\nSection 8.7",
            "Termination Fees (see page 83)\nUpon termination of the Merger Agreement under specified circumstances, Magellan will be required to pay Centene\na termination fee of $76,530,000. For additional information, see the section entitled \u201cThe Merger Agreement-\nTermination Fees,\u201d beginning on page 83.",
            "Section 6.3 Conditions to Obligations of the Company. The obligation of the Company to consummate the Merger\nis subject to the satisfaction (or waiver by the Company) at or prior to the Closing of the following conditions:\n(a) Representations and Warranties. Each representation and warranty in Article IV shall be accurate in all\nrespects (read, for purposes of this Section 6.3(a) only, without any qualification as to \u201cmaterial,\u201d \u201cin all material\nrespects,\u201d \u201cParent Material Adverse Effect\u201d or materiality) as of the date hereof and as of the Closing as if made\nas of the Closing (except to the extent any such representation or warranty expressly speaks as of the date\nhereof or any other specific date, in which case such representation or warranty shall have been accurate in all\nrespects as of such date), except for any failure of any such representation and warranty to be true and correct\nas would not reasonably be expected to result in, individually or in the aggregate, a Parent Material Adverse\nEffect.\n(b) Covenants and Agreements. Each of Parent and Merger Sub shall have performed or complied in all\nmaterial respects with all of the covenants and agreements hereunder that this Agreement requires Parent or\nMerger Sub to perform or comply with at or prior to the Closing.\n(c) Bringdown Certificate. The Company shall have received a certificate, dated as of the Closing Date and\nduly executed by an executive officer of Parent, certifying the satisfaction of all conditions in Section 6.3(a) and\nSection 6.3(b).\nARTICLE VII\n \nTERMINATION\nSection 7.1",
            "Section 6.1 Conditions to Obligations of Each Party. The respective obligations of Parent and Merger Sub, on the\none hand, and the Company, on the other hand, to consummate the Merger are subject to the satisfaction (or waiver\nby Parent and the Company) at or prior to the Closing of the following conditions:\n(a) Company Stockholder Approval. The Company Stockholder Approval shall have been obtained.\n(b) No Legal Restraint. No Law, whether preliminary, temporary or permanent, shall be in effect that prevents,\nmakes illegal or prohibits the Merger (any such Law, a \u201cLegal Restraint\u201d).\n(c) Governmental Consents. (i) The waiting period (and any extension of such period, including any agreement\nbetween a Party and a Governmental Authority agreeing not to consummate the Merger prior to a certain date)\nunder the HSR Act applicable to the transactions contemplated hereby shall have expired or otherwise been\nterminated (the \u201cHSR Clearance\u201d) and (ii) all Filings with or to, and all Consents of, any Governmental Authority\nlisted in Exhibit A (the \u201cRequired Filings\u201d and the \u201cRequired Consents,\u201d respectively) shall have been made or\nobtained, respectively.\nSection 6.2"
        ],
        [
            "Section 5.8 Indemnification.\n(a) From and after the Effective Time, Parent shall cause the Surviving Corporation and its Subsidiaries to fulfill\nand honor in all respects the obligations of the Company Entities imposed under (i) each indemnification\nagreement between any Company Entity and any Indemnified Person (the \u201cCompany Indemnification\nAgreements\u201d) and (ii) any indemnification provision and any exculpation provision in the Constituent\nDocuments of the Company Entities as in effect on the date hereof. The Constituent Documents of the\nSurviving Corporation and the Surviving Corporation\u2019s Subsidiaries shall contain provisions related to\nindemnification and exculpation from liability no less favorable than the indemnification, exculpation from\nliability and advancement of expenses provisions in the Constituent Documents of the Company or its relevant\nSubsidiaries on the date hereof, and, during the period commencing at the Effective Time and ending on the\nsixth (6th) anniversary of the Closing Date, such provisions shall not be amended, repealed or otherwise\nmodified in any manner that could adversely affect the rights thereunder of any Indemnified Person.\n(b) During the period commencing at the Effective Time and ending on the sixth (6th) anniversary of the\nClosing Date, Parent shall cause the Surviving Corporation or its applicable Subsidiaries to, indemnify and hold\nharmless, and advance expenses to, the Indemnified Persons against any out-of-pocket costs or expenses\n(including reasonable attorneys\u2019 fees), judgments, fines, losses, claims, damages or liabilities in connection with\nany actual or threatened Action arising out of or relating to (i) the fact that such Indemnified Person is or was a\ndirector, officer, employee or agent of any Company Entity, (ii) any acts or omissions occurring or alleged to\noccur prior to or at the Effective Time in such Indemnified Person\u2019s capacity as a director or officer of any\nCompany Entity, whether asserted or claimed prior to, at or after the Effective Time or (iii) the Merger, this\nAgreement or the transactions contemplated hereby, in each case, to the fullest extent permitted by applicable\nLaw, any applicable Company Indemnification Agreement and the Constituent Documents in effect as of the\ndate hereof.\n(c) Through the sixth (6th) anniversary of the Closing Date, Parent shall cause the Surviving Corporation or its\napplicable Subsidiaries to maintain in effect, for the benefit of the Indemnified Persons, a level and scope of\ndirectors\u2019 and officers\u2019 liability insurance coverage at least as favorable as the level and scope thereof set forth\nin the Company\u2019s current directors\u2019 and officers\u2019 liability insurance program in effect as of the date hereof and\nmade available to Parent\u037e provided, however, that in no event shall the Surviving Corporation be required to\nexpend in any one (1) year an amount in excess of 300% of the annual premium currently payable by the\nCompany related to such current policy (the \u201cAnnual Cap\u201d)\u037e provided, further, that, if the annual premiums\npayable for such insurance coverage exceed the Annual Cap, the Surviving Corporation shall obtain a policy\nwith the greatest coverage available for a cost equal to the Annual Cap. In lieu of the obligations in, and\nnotwithstanding anything in, the immediately preceding sentence, the Company, in consultation with Parent,\nmay obtain a prepaid \u201ctail\u201d policy prior to the Effective Time that provides the Indemnified Persons with\ndirectors\u2019 and officers\u2019 liability insurance for a period ending no earlier than the sixth (6th) anniversary of the\nClosing Date\u037e provided that the annual premiums payable for such \u201ctail\u201d policy shall not exceed the Annual\nCap.\n(d) If Parent or the Surviving Corporation or any of their successors or assigns shall (i) consolidate with or\nmerge into any other Person and shall not be the continuing or surviving corporation or entity of such\nconsolidation or merger or (ii) transfer all or substantially all of its properties and assets to any Person, then, and\nin each such case, proper provisions shall be made so that the successors and assigns of Parent or the\nSurviving Corporation, as the case may be, shall assume all of the obligations of the Surviving Corporation (or\nParent) under this Section 5.8.\nA-39TABLE OF CONTENTS\n(e) From and after the Closing, the Indemnified Persons shall be third-party beneficiaries of this Section 5.8,\nwith full rights of enforcement as if a party hereto. The rights of the Indemnified Persons under this Section 5.8\nshall be in addition to, and not in substitution for, any other rights that any such Indemnified Person may have\nunder the applicable Constituent Documents or any Company Indemnification Agreement.\n(f) Nothing herein is intended to, shall be construed to or shall release, waive or impair any rights to directors\u2019\nand officers\u2019 insurance claims under any policy that is or has been in existence related to the Company Entities\nfor any of their respective directors, officers or other employees, it being understood and agreed that the\nindemnification provided for in this Section 5.8 is not prior to or in substitution for any such claims under such\npolicies.\n(g) As used herein, \u201cIndemnified Person\u201d means any Person who is or was an officer, director or employee of\nany Company Entity at or at any time prior to the Effective Time.\nSection 5.9",
            "TABLE OF CONTENTS\nAnnex C\nPERSONAL AND CONFIDENTIAL\nJanuary 4, 2021\nBoard of Directors \nMagellan Health, Inc.\n4800 Scottsdale Road, Suite 4400\nScottsdale, Arizona 85251\nLadies and Gentlemen:\nYou have requested our opinion as to the fairness from a financial point of view to the holders (other than Centene\nCorporation (\u201cCentene\u201d) and its affiliates) of the outstanding shares of common stock, par value $0.01 per share (the\n\u201cShares\u201d), of Magellan Health, Inc. (the \u201cCompany\u201d) of the $95.00 in cash per Share to be paid to such holders\npursuant to the Agreement and Plan of Merger, dated as of January 4, 2021 (the \u201cAgreement\u201d), by and among\nCentene, Mayflower Merger Sub, Inc., a wholly owned subsidiary of Centene, and the Company.\nGoldman Sachs & Co. LLC and its affiliates are engaged in advisory, underwriting and financing, principal investing,\nsales and trading, research, investment management and other financial and non-financial activities and services for\nvarious persons and entities. Goldman Sachs & Co. LLC and its affiliates and employees, and funds or other entities\nthey manage or in which they invest or have other economic interests or with which they co-invest, may at any time\npurchase, sell, hold or vote long or short positions and investments in securities, derivatives, loans, commodities,\ncurrencies, credit default swaps and other financial instruments of the Company, Centene, any of their respective\naffiliates and third parties, or any currency or commodity that may be involved in the transaction contemplated by the\nAgreement (the \u201cTransaction\u201d). We have acted as financial advisor to the Company in connection with, and have\nparticipated in certain of the negotiations leading to, the Transaction. We expect to receive fees for our services in\nconnection with the Transaction, all of which are contingent upon consummation of the Transaction, and the\nCompany has agreed to reimburse certain of our expenses arising, and indemnify us against certain liabilities that may\narise, out of our engagement. We have provided certain financial advisory and/or underwriting services to the\nCompany and/or its affiliates from time to time for which our Investment Banking Division has received, and may\nreceive, compensation. We may also in the future provide financial advisory and/or underwriting services to the\nCompany, Centene and their respective affiliates for which our Investment Banking Division may receive\ncompensation.\nIn connection with this opinion, we have reviewed, among other things, the Agreement\u037e annual reports to\nstockholders and Annual Reports on Form 10-K of the Company for the five years ended December 31, 2019\u037e certain\ninterim reports to stockholders and Quarterly Reports on Form 10-Q of the Company\u037e certain other communications\nfrom the Company to its stockholders\u037e certain publicly available research analyst reports for the Company\u037e and\ncertain internal financial analyses and forecasts for the Company prepared by its management, as approved for our\nuse by the Company (the \u201cForecasts\u201d). We have also held discussions with members of the senior management of\nthe Company regarding their assessment of the past and current business operations, financial condition and future\nprospects of the Company\u037e reviewed the reported price and trading activity for the Shares\u037e compared certain financial\nand stock market information for the Company with similar information for certain other companies the securities of\nwhich are publicly traded\u037e reviewed the financial terms of certain recent business combinations in the Healthcare\nindustry\u037e and performed such other studies and analyses, and considered such other factors, as we deemed\nappropriate.\nFor purposes of rendering this opinion, we have, with your consent, relied upon and assumed the accuracy and\ncompleteness of all of the financial, legal, regulatory, tax, accounting and other information provided to, discussed\nwith or reviewed by, us, without assuming any responsibility for independent verification thereof. In that regard, we\nhave assumed with your consent that the Forecasts have been reasonably prepared on a basis reflecting the best\ncurrently available estimates and judgments of the management of the Company. We have not made an independent\nevaluation or appraisal of the assets and liabilities (including any contingent, derivative or other off-balance-sheet\nassets and liabilities) of the Company or any of its subsidiaries and we have not been furnished with any such\nevaluation or appraisal. We have assumed that all governmental, regulatory or other consents and approvals\nnecessary for the consummation of the Transaction will be obtained without any adverse\nC-1\n",
            "Section 3.13 Taxes. Except as has not resulted in and would not reasonably be expected to result in, individually or\nin the aggregate, a Company Material Adverse Effect:\n(a) each Company Entity has timely filed all Tax Returns required to be filed (taking into account any\nextensions of time within which to file such Tax Returns), and all such Tax Returns were complete and correct,\nand the Company Entities have paid all Taxes that are required to be paid by them, whether or not shown to be\ndue on such Tax Returns, or have established an adequate reserve therefor in accordance with GAAP\u037e\n(b) there are no current audits, examinations or other proceedings pending or, to the Company\u2019s Knowledge,\nthreatened in writing with regard to any Taxes of any Company Entity\u037e\n(c) no Company Entity has granted any extension or waiver of the limitation period applicable to the\nassessment or collection of any Tax that is currently in effect\u037e\n(d) there are no Liens for Taxes upon any property or assets of the Company Entities, except for Permitted\nLiens\u037e\n(e) no Company Entity (i) is or has been a member of an affiliated, consolidated, combined, unitary or similar\ngroup for purposes of filing Tax Returns or paying Taxes (other than a group the common parent of which is the\nCompany), (ii) is party to any Tax sharing, Tax allocation or Tax indemnity agreement or similar contract or\narrangement under which any Company Entity has any remaining obligations, in each case with any third party\n(other than customary Tax indemnification provisions in commercial agreements or arrangements, in each case\nnot primarily relating to Taxes, including, for the avoidance of doubt, the MCC Transaction Agreement, or any\nagreement solely between or among the Company Entities) or (iii) has any Liability for Taxes of any Person\n(other than the Company Entities) arising from the application of Treasury Regulation Section 1.1502-6 or any\nanalogous provision of state, local or foreign Law or as a transferee or successor\u037e\n(f) no Company Entity has been a party to any \u201clisted transaction\u201d within the meaning of Section 6011 of the\nCode and the regulations thereunder\u037e and\n(g) in the last two (2) years, no Company Entity has distributed stock of another Person or has had its stock\ndistributed by another Person in a transaction that was purported or intended to be governed in whole or in part\nby Section 355 of the Code.",
            "Solicitation of Proxies\nMagellan is soliciting the enclosed proxy card on behalf of the Board, and Magellan will bear the expenses in\nconnection with the solicitation of proxies. In addition to solicitation by mail, Magellan and its directors, officers and\nemployees may solicit proxies in person, by telephone or by electronic means. These persons will not be specifically\ncompensated for doing this.\nMagellan has retained MacKenzie Partners to assist in the solicitation process. Magellan will pay MacKenzie\nPartners a fee of approximately $20,000 plus reimbursement of certain specified out-of-pocket expenses. Magellan\nalso has agreed to indemnify MacKenzie Partners against various liabilities and expenses that relate to or arise out of\nits solicitation of proxies (subject to certain exceptions).\nMagellan will ask banks, brokers, trusts and other nominees to forward Magellan\u2019s proxy solicitation materials to the\nbeneficial owners of shares of Magellan common stock held of record by such banks, brokers, trusts or other\nnominees. Magellan will reimburse these banks, brokers, trusts or other nominees for their customary clerical and\nmailing expenses incurred in forwarding the proxy solicitation materials to the beneficial owners.\n24TABLE OF CONTENTS",
            "Annex D\n \nGuggenheim Securities, LLC\n330 Madison Avenue\nNew York, New York 10017\nGuggenheimPartners.com\nJanuary 4, 2021\nThe Board of Directors\nMagellan Health, Inc.\n4801 E. Washington Street\nPhoenix, Arizona 85034\nMembers of the Board:\nWe understand that Magellan Health, Inc. (\u201cMagellan Health\u201d) and Centene Corporation (\u201cCentene\u201d) intend to enter\ninto an Agreement and Plan of Merger to be dated as of January 4, 2021 (the \u201cAgreement\u201d), pursuant to which\nMayflower Merger Sub, Inc., a wholly owned subsidiary of Centene (\u201cMerger Sub\u201d), will merge with and into\nMagellan Health (the \u201cMerger\u201d) and Magellan Health will become a wholly owned subsidiary of Centene. Pursuant to\nthe Agreement, each of the issued and outstanding shares (the \u201cShares\u201d) of the common stock, par value $0.01 per\nshare, of Magellan Health will (subject to certain exceptions) be converted into the right to receive $95.00 in cash (the\n\u201cMerger Consideration\u201d). The terms and conditions of the Merger are more fully set forth in the Agreement.\nYou have asked us to render our opinion as to whether the Merger Consideration is fair, from a financial point of view,\nto the holders of Shares.\nIn connection with rendering our opinion, we have:\n\u2022\nReviewed a draft of the Agreement dated as of January 2, 2021\u037e\n\u2022\nReviewed certain publicly available business and financial information regarding Magellan Health\u037e\n\u2022\nReviewed certain non-public business and financial information regarding Magellan Health\u2019s business and\nfuture prospects (including certain financial projections for Magellan Health on a stand-alone basis for the\nyears ending December 31, 2020 through December 31, 2024 (the \u201cFinancial Projections\u201d) and certain other\nestimates and other forward-looking information), all as prepared and approved for our use by Magellan\nHealth\u2019s senior management (collectively, the \u201cMagellan Health-Provided Information\u201d)\u037e\n\u2022\nDiscussed with Magellan Health\u2019s senior management their views of Magellan Health\u2019s business,\noperations, historical and projected financial results and future prospects and the commercial, competitive\nand regulatory dynamics in the healthcare sector\u037e\n\u2022\nPerformed discounted cash flow analyses based on the Financial Projections\u037e\n\u2022\nReviewed the valuation and financial metrics of certain mergers and acquisitions that we deemed relevant in\nevaluating the Merger\u037e\n\u2022\nReviewed the historical prices and trading multiples of the Shares\u037e\n\u2022\nCompared the financial performance of Magellan Health and the trading multiples and trading activity of\nthe Shares with corresponding data for certain other publicly traded companies that we deemed relevant in\nevaluating Magellan Health\u037e and\n\u2022\nConducted such other studies, analyses, inquiries and investigations as we deemed appropriate.\nD-1TABLE OF CONTENTS\nThe Board of Directors \nMagellan Health, Inc. \nJanuary 4, 2021 \nPage 2 \nWith respect to the information used in arriving at our opinion:\n\u2022\nWe have relied upon and assumed the accuracy, completeness and reasonableness of all industry,\nbusiness, financial, legal, regulatory, tax, accounting, actuarial and other information provided by or\ndiscussed with Magellan Health (including, without limitation, the Magellan Health-Provided Information)\nor obtained from public sources, data suppliers and other third parties.\n\u2022\nWe (i) do not assume any responsibility, obligation or liability for the accuracy, completeness,\nreasonableness, achievability or independent verification of, and we have not independently verified, any\nsuch information (including, without limitation, the Magellan Health-Provided Information), (ii) express no\nview or opinion regarding the reasonableness or achievability of the Financial Projections, any other\nestimates and any other forward-looking information provided by Magellan Health or the assumptions\nupon which any of the foregoing are based and (iii) have relied upon the assurances of Magellan Health\u2019s\nsenior management that they are unaware of any facts or circumstances that would make the Magellan\nHealth-Provided Information incomplete, inaccurate or misleading.\n\u2022\nSpecifically, with respect to (i) the Financial Projections utilized in our analyses, (a) we have been advised\nby Magellan Health\u2019s senior management, and we have assumed, that the Financial Projections have been\nreasonably prepared on bases reflecting the best currently available estimates and judgments of Magellan\nHealth\u2019s senior management as to the expected future performance of Magellan Health on a stand-alone\nbasis and (b) we have assumed that the Financial Projections have been reviewed by Magellan Health\u2019s\nBoard of Directors with the understanding that such information will be used and relied upon by us in\nconnection with rendering our opinion and (ii) any financial projections/forecasts, any other estimates\nand/or any other forward-looking information obtained by us from public sources, data suppliers and other\nthird parties, we have assumed that such information is reasonable and reliable.\nDuring the course of our engagement, we were not asked by Magellan Health\u2019s Board of Directors to, and we did not,\nsolicit indications of interest from any potential third-party transaction counterparties regarding a potential\nextraordinary corporate transaction with or involving Magellan Health.\nIn arriving at our opinion, we have not performed or obtained any independent appraisal of the assets or liabilities\n(including any contingent, derivative or off-balance sheet assets and liabilities) of Magellan Health or any other\nentity or the solvency or fair value of Magellan Health or any other entity, nor have we been furnished with any such\nappraisals. We are not legal, regulatory, tax, consulting, accounting, appraisal or actuarial experts and nothing in our\nopinion should be construed as constituting advice with respect to such matters\u037e accordingly, we have relied on the\nassessments of Magellan Health\u2019s senior management and Magellan Health\u2019s other professional advisors with\nrespect to such matters.\nIn rendering our opinion, we have assumed that, in all respects meaningful to our analyses, (i) the final executed form\nof the Agreement will not differ from the draft that we have reviewed, (ii) Magellan Health, Centene and Merger Sub\nwill comply with all terms and provisions of the Agreement and (iii) the representations and warranties of Magellan\nHealth, Centene and Merger Sub contained in the Agreement are true and correct and all conditions to the\nobligations of each party to the Agreement to consummate the Merger will be satisfied without any waiver,\namendment or modification thereof. We also have assumed that the Merger will be consummated in a timely manner\nin accordance with the terms of the Agreement and in compliance with all applicable legal and other requirements,\nwithout any delays, limitations, restrictions, conditions, divestiture or other requirements, waivers, amendments or\nmodifications (regulatory, tax-related or otherwise) that would have an effect on Magellan Health or the Merger in\nany way meaningful to our analyses or opinion.\nIn rendering our opinion, we do not express any view or opinion as to the price or range of prices at which the Shares\nor other securities or financial instruments of or relating to Magellan Health may trade or otherwise be transferable at\nany time, including subsequent to the announcement or consummation of the Merger.\nD-2\nTABLE OF CONTENTS\nThe Board of Directors \nMagellan Health, Inc.\nJanuary 4, 2021 \nPage 3\nWe have acted as a financial advisor to Magellan Health in connection with the Merger and will receive a customary\nfee for such services upon successful consummation of the Merger. In addition, Magellan Health has agreed to\nreimburse us for certain expenses and to indemnify us against certain liabilities arising out of our engagement.\nAs previously disclosed, aside from our current engagement by Magellan Health, we have not been previously\nengaged during the past two years by Magellan Health, nor have we been previously engaged during the past two\nyears by Centene, to provide financial advisory or investment banking services for which we received fees. We may\nseek to provide Magellan Health and Centene and their respective affiliates with financial advisory and investment\nbanking services unrelated to the Merger in the future, for which services we would expect to receive compensation.\nWe and our affiliates and related entities engage in a wide range of financial services activities for our and their own\naccounts and the accounts of customers, including but not limited to: asset, investment and wealth management\u037e\ninsurance services\u037e investment banking, corporate finance, mergers and acquisitions and restructuring\u037e merchant\nbanking\u037e fixed income and equity sales, trading and research\u037e and derivatives, foreign exchange and futures. In the\nordinary course of these activities, we and our affiliates and related entities may (i) provide such financial services to\nMagellan Health, Centene, other participants in the Merger and their respective affiliates, for which services we and\nour affiliates and related entities may have received, and may in the future receive, compensation and (ii) directly and\nindirectly hold long and short positions, trade and otherwise conduct such activities in or with respect to loans, debt\nand equity securities and derivative products of or relating to Magellan Health, Centene, other participants in the\nTransaction and their respective affiliates. Furthermore, we and our affiliates and related entities and our or their\nrespective directors, officers, employees, consultants and agents may have investments in Magellan Health, Centene,\nother participants in the Transaction and their respective affiliates.\nConsistent with applicable legal and regulatory guidelines, we have adopted certain policies and procedures to\nestablish and maintain the independence of our research departments and personnel. As a result, our research\nanalysts may hold views, make statements or investment recommendations and publish research reports with respect\nto Magellan Health, Centene, other participants in the Transaction and their respective affiliates and the Merger that\ndiffer from the views of our investment banking personnel.\nOur opinion has been provided to Magellan Health\u2019s Board of Directors (in its capacity as such) for its information\nand assistance in connection with its evaluation of the Merger Consideration. Our opinion may not be disclosed\npublicly, made available to third parties or reproduced, disseminated, quoted from or referred to at any time, in whole\nor in part, without our prior written consent\u037e provided, however, that this letter may be included in its entirety in any\nproxy statement to be distributed to the holders of Shares in connection with the Merger.\nOur opinion and any materials provided in connection therewith do not constitute a recommendation to Magellan\nHealth\u2019s Board of Directors with respect to the Merger, nor does our opinion or any summary of our underlying\nanalyses constitute advice or a recommendation to any holder of Shares as to how to vote or act in connection with\nthe Merger or otherwise. Our opinion does not address Magellan Health\u2019s underlying business or financial decision\nto pursue or effect the Merger, the relative merits of the Merger as compared to any alternative business or the\neffects of any other transaction in which Magellan Health might engage. Our opinion addresses only the fairness,\nfrom a financial point of view and as of the date hereof, of the Merger Consideration to the holders of Shares. We do\nnot express any view or opinion as to (i) any other term, aspect or implication of (a) the Merger (including, without\nlimitation, the form or structure of the Merger) or the Agreement or (b) any voting and support agreement or any\nother agreement, transaction document or instrument contemplated by the Agreement or to be entered into or\namended in connection with the Merger or (ii) the fairness, financial or otherwise, of the Merger to, or of any\nconsideration to be paid to or received by, the holders of any class of securities (other than as expressly specified\nherein), creditors or other constituencies of Magellan Health.\nD-3\nTABLE OF CONTENTS\nThe Board of Directors \nMagellan Health, Inc.\nJanuary 4, 2021 \nPage 4 \n\u2003 \nFurthermore, we do not express any view or opinion as to the fairness, financial or otherwise, of the amount or nature\nof any compensation payable to or to be received by any of Magellan Health\u2019s directors, officers or employees, or\nany class of such persons, in connection with the Merger relative to the Merger Consideration or otherwise.\nOur opinion has been authorized for issuance by our Fairness Opinion and Valuation Committee. Our opinion is\nsubject to the assumptions, limitations, qualifications and other conditions contained herein and is necessarily based\non economic, business, capital markets and other conditions, and the information made available to us, as of the date\nhereof. As Magellan Health is aware, global economic conditions and the global capital markets have been\nexperiencing and remain subject to significant volatility, and Guggenheim Securities expresses no view or opinion as\nto any potential effects of such volatility on Magellan Health, Centene or the Merger. We assume no responsibility\nfor updating or revising our opinion based on facts, circumstances or events occurring after the date hereof.\nBased on and subject to the foregoing, it is our opinion that, as of the date hereof, the Merger Consideration is fair,\nfrom a financial point of view, to the holders of Shares.\nVery truly yours,\n/s/ Guggenheim Securities, LLC\nGUGGENHEIM SECURITIES, LLC\nD-4\nTABLE OF CONTENTS\nAnnex E\nGENERAL CORPORATION LAW OF THE STATE OF DELAWARE",
            "Annex C\nPERSONAL AND CONFIDENTIAL\nJanuary 4, 2021\nBoard of Directors \nMagellan Health, Inc.\n4800 Scottsdale Road, Suite 4400\nScottsdale, Arizona 85251\nLadies and Gentlemen:\nYou have requested our opinion as to the fairness from a financial point of view to the holders (other than Centene\nCorporation (\u201cCentene\u201d) and its affiliates) of the outstanding shares of common stock, par value $0.01 per share (the\n\u201cShares\u201d), of Magellan Health, Inc. (the \u201cCompany\u201d) of the $95.00 in cash per Share to be paid to such holders\npursuant to the Agreement and Plan of Merger, dated as of January 4, 2021 (the \u201cAgreement\u201d), by and among\nCentene, Mayflower Merger Sub, Inc., a wholly owned subsidiary of Centene, and the Company.\nGoldman Sachs & Co. LLC and its affiliates are engaged in advisory, underwriting and financing, principal investing,\nsales and trading, research, investment management and other financial and non-financial activities and services for\nvarious persons and entities. Goldman Sachs & Co. LLC and its affiliates and employees, and funds or other entities\nthey manage or in which they invest or have other economic interests or with which they co-invest, may at any time\npurchase, sell, hold or vote long or short positions and investments in securities, derivatives, loans, commodities,\ncurrencies, credit default swaps and other financial instruments of the Company, Centene, any of their respective\naffiliates and third parties, or any currency or commodity that may be involved in the transaction contemplated by the\nAgreement (the \u201cTransaction\u201d). We have acted as financial advisor to the Company in connection with, and have\nparticipated in certain of the negotiations leading to, the Transaction. We expect to receive fees for our services in\nconnection with the Transaction, all of which are contingent upon consummation of the Transaction, and the\nCompany has agreed to reimburse certain of our expenses arising, and indemnify us against certain liabilities that may\narise, out of our engagement. We have provided certain financial advisory and/or underwriting services to the\nCompany and/or its affiliates from time to time for which our Investment Banking Division has received, and may\nreceive, compensation. We may also in the future provide financial advisory and/or underwriting services to the\nCompany, Centene and their respective affiliates for which our Investment Banking Division may receive\ncompensation.\nIn connection with this opinion, we have reviewed, among other things, the Agreement\u037e annual reports to\nstockholders and Annual Reports on Form 10-K of the Company for the five years ended December 31, 2019\u037e certain\ninterim reports to stockholders and Quarterly Reports on Form 10-Q of the Company\u037e certain other communications\nfrom the Company to its stockholders\u037e certain publicly available research analyst reports for the Company\u037e and\ncertain internal financial analyses and forecasts for the Company prepared by its management, as approved for our\nuse by the Company (the \u201cForecasts\u201d). We have also held discussions with members of the senior management of\nthe Company regarding their assessment of the past and current business operations, financial condition and future\nprospects of the Company\u037e reviewed the reported price and trading activity for the Shares\u037e compared certain financial\nand stock market information for the Company with similar information for certain other companies the securities of\nwhich are publicly traded\u037e reviewed the financial terms of certain recent business combinations in the Healthcare\nindustry\u037e and performed such other studies and analyses, and considered such other factors, as we deemed\nappropriate.\nFor purposes of rendering this opinion, we have, with your consent, relied upon and assumed the accuracy and\ncompleteness of all of the financial, legal, regulatory, tax, accounting and other information provided to, discussed\nwith or reviewed by, us, without assuming any responsibility for independent verification thereof. In that regard, we\nhave assumed with your consent that the Forecasts have been reasonably prepared on a basis reflecting the best\ncurrently available estimates and judgments of the management of the Company. We have not made an independent\nevaluation or appraisal of the assets and liabilities (including any contingent, derivative or other off-balance-sheet\nassets and liabilities) of the Company or any of its subsidiaries and we have not been furnished with any such\nevaluation or appraisal. We have assumed that all governmental, regulatory or other consents and approvals\nnecessary for the consummation of the Transaction will be obtained without any adverse\nC-1TABLE OF CONTENTS\nBoard of Directors \nMagellan Health, Inc. \nJanuary 4, 2021 \nPage 2\n\u2003 \neffect on the Company or Centene or on the expected benefits of the Transaction in any way meaningful to our\nanalysis. We have assumed that the Transaction will be consummated on the terms set forth in the Agreement,\nwithout the waiver or modification of any term or condition the effect of which would be in any way meaningful to\nour analysis.\nOur opinion does not address the underlying business decision of the Company to engage in the Transaction, or the\nrelative merits of the Transaction as compared to any strategic alternatives that may be available to the Company\u037e nor\ndoes it address any legal, regulatory, tax or accounting matters. We were not requested to solicit, and did not solicit,\ninterest from other parties with respect to an acquisition of, or other business combination with, the Company or any\nother alternative transaction. This opinion addresses only the fairness from a financial point of view to the holders\n(other than Centene and its affiliates) of Shares, as of the date hereof, of the $95.00 in cash per Share to be paid to\nsuch holders pursuant to the Agreement. We do not express any view on, and our opinion does not address, any\nother term or aspect of the Agreement or Transaction or any term or aspect of any other agreement or instrument\ncontemplated by the Agreement or entered into or amended in connection with the Transaction, including, the\nfairness of the Transaction to, or any consideration received in connection therewith by, the holders of any other\nclass of securities, creditors, or other constituencies of the Company\u037e nor as to the fairness of the amount or nature\nof any compensation to be paid or payable to any of the officers, directors or employees of the Company, or class of\nsuch persons, in connection with the Transaction, whether relative to the $95.00 in cash per Share to be paid to the\nholders (other than Centene and its affiliates) of Shares pursuant to the Agreement or otherwise. We are not\nexpressing any opinion as to the prices at which the Shares will trade at any time or, as to the potential effects of\nvolatility in the credit, financial and stock markets on the Company or Centene or the Transaction, or as to the impact\nof the Transaction on the solvency or viability of the Company or Centene or the ability of the Company or Centene\nto pay their respective obligations when they come due. Our opinion is necessarily based on economic, monetary,\nmarket and other conditions as in effect on, and the information made available to us as of, the date hereof and we\nassume no responsibility for updating, revising or reaffirming this opinion based on circumstances, developments or\nevents occurring after the date hereof. Our advisory services and the opinion expressed herein are provided for the\ninformation and assistance of the Board of Directors of the Company in connection with its consideration of the\nTransaction and such opinion does not constitute a recommendation as to how any holder of Shares should vote\nwith respect to such Transaction or any other matter. This opinion has been approved by a fairness committee of\nGoldman Sachs & Co. LLC.\nBased upon and subject to the foregoing, it is our opinion that, as of the date hereof, the $95.00 in cash per Share to\nbe paid to the holders (other than Centene and its affiliates) of Shares pursuant to the Agreement is fair from a\nfinancial point of view to such holders.\nVery truly yours,\n/s/ Goldman Sachs & Co. LLC\n(GOLDMAN SACHS & CO. LLC)\nC-2\nTABLE OF CONTENTS\nAnnex D"
        ],
        [
            "Section 3.16 Data Protection and Privacy.\n(a) Except as has not resulted in and would not reasonably be expected to result in, individually or in the\naggregate, a Company Material Adverse Effect:\n(i) (1) each Company Entity maintains, and since December 31, 2017, has adopted, implemented and\nmaintained a data privacy and security compliance program that complies with all applicable\nPrivacy/Cybersecurity Requirements, protects Company IT Assets and protects Personal Information in\nthe possession or under the control of any Company Entity against reasonably anticipated threats and\nhazards to its security and the unauthorized use or disclosure thereof, and that includes reasonably\ncomprehensive plans, policies, procedures and administrative, personnel, technical and physical\nsafeguards to protect the Company IT Assets and Personal Information and other material data in the\npossession or under the control of any Company Entity, (2) the Company Entities are, and since December\n31, 2017, have been, in compliance with all Privacy/Cybersecurity Requirements, including all HIPAA\nCommitments and requirements set forth in Company Entity data privacy and security compliance program\npolicies, in the business of the Company Entities, (3) since December 31, 2017, no Person has gained\nunauthorized access, including any such access reportable to a Governmental Authority under applicable\nLaw, to any Personal Information transmitted, processed or stored by or in the possession or under the\ncontrol of any Company Entity or to any Company IT Assets, or used, accessed or disclosed any such\nPersonal Information or used or accessed such Company IT Assets for any illegal or unauthorized\npurpose, (4) since December 31, 2017, no Company Entity has received written notice of any claims, and\nthere have been no Actions (including any investigation or written notice), from any Governmental\nAuthority or any other Person alleging either a violation of any Person\u2019s rights under\nPrivacy/Cybersecurity Requirements, or breach or compromise of Privacy/Cybersecurity Requirements and\n(5) the consummation of the transactions contemplated hereby shall not breach or otherwise cause any\nviolation of Privacy/Cybersecurity Requirements\u037e and\n(ii) without limiting Section 3.16(a)(i), since December 31, 2017, (1) no Company Entity has received any\nnotice from any Governmental Authority or other Person in respect of any alleged\nA-22TABLE OF CONTENTS\nnoncompliance with HIPAA, including the HIPAA Commitments, or any other Privacy/Cybersecurity\nRequirements, (2) no breach, unauthorized access or other actual or potential noncompliance related to\nPrivacy/Cybersecurity Requirements has occurred, including any breach as that term is defined in 45 C.F.R.\n\u00a7160.103, related to any unsecured Personal Information that is created, retained, collected, used,\ndisclosed, stored, transmitted, received or otherwise processed by a Company Entity, (3) no information\nsecurity or privacy breach event has occurred that has resulted in or would require notification to any\nGovernmental Authority or other Person by, on behalf of or as a result of a Company Entity under HIPAA\nor any comparable Laws or other Privacy/Cybersecurity Requirements, including any report of a breach or\nsimilar event to the Office for Civil Rights of the Department of Health and Human Services, (4) no Action\nhas been asserted or threatened against any Company Entity alleging a violation of any Person\u2019s data\nprivacy or security rights, or a violation of any Privacy/Cybersecurity Requirement, and there does not\nexist any colorable basis therefor and (5) no Company Entity is or has been in breach or default under any\nContract related to any provision thereof related to the creation, collection, obtaining, tracking, retention,\nstorage, processing, use, sharing, disclosure, transmission, security, confidentiality and/or protection of\nCompany IT Assets or Personal Information.\n(b) The Company is not subject to any Privacy/Cybersecurity Requirements that, after the Closing, would\nprohibit the Company Entities from receiving and/or using Personal Information in substantially the same\nmanner as prior to the Closing.\nSection 3.17",
            "Section 5.6 Access to Information. Upon reasonable notice, and except as may otherwise be required by applicable\nLaw, the Company shall provide Parent and its Representatives reasonable access, during normal business hours\nthroughout the period prior to the Effective Time, to the Company Entities\u2019 properties, books, records and personnel,\nand during such period, the Company shall cause to be furnished promptly to Parent, its Representatives and, to the\nextent provided in Section 5.9, its Financing Sources, all information concerning the Company Entities and their\nrespective businesses, as Parent or the Financing Sources may reasonably request, including copies of such\ninformation as is necessary for the operation, ownership and management of the Company Entities\u2019 business or\ninformation as may be required to permit Parent to satisfy its obligations to any Governmental Authority following\nthe Effective Time (but in the case of the Financing Sources, only if relevant to the Financing)\u037e provided that Parent\nand the Financing Sources shall not use any information obtained under this Section 5.6 for any purpose unrelated to\nthe Merger or the other transactions contemplated hereby\u037e provided, however, that the Company shall not be\nrequired to (a) permit any invasive environmental sampling or (b) provide any such access or information that in the\nreasonable, good-faith judgment of the Company (i) would be reasonably likely to result in the disclosure of any\ntrade secrets of third parties or breach any confidentiality obligation of any Company Entity\u037e provided that the\nCompany, subject to the provisions of Section 5.7(a), shall use reasonable best efforts to obtain the required consent\nof such third party to provide such access or disclosure, (ii) would be reasonably likely to jeopardize protections\nafforded any Company Entity under the attorney-client privilege\u037e provided that the Company shall use reasonable\nbest efforts to allow for such access or disclosure to the maximum extent that does not result in a loss of attorney-\nclient privilege or (iii) any applicable Law requires the Company or any Company Subsidiary to restrict or prohibit\naccess to any such properties or information\u037e provided, further, that (A) the Company shall promptly notify Parent in\nwriting if any reason described in the foregoing clauses (b)(i), (b)(ii) or (b)(iii) is applicable to any request for\ninformation and (B) if any such access or information is limited for the reasons described in the foregoing clauses (b)\n(i), (b)(ii) or (b)(iii), Parent and the Company shall use their respective reasonable best efforts to establish a process\nthat (through use of steps such as targeted redactions, provision of information to counsel to review and summarize\nfor Parent, use of a \u201cclean room\u201d environment for analysis and review of information by appropriate recipients in\ncoordination with counsel and the Company or, in the case of clause (b)(ii), entry into a customary joint defense\nagreement with respect to any information to be so provided, if the Parties determine that doing so would reasonably\npermit the disclosure of such information without violating applicable Law or losing such privilege) shall provide\nParent with timely access to the fullest extent possible to the substance of the information described in this Section\n5.6. All information obtained by Parent and its Representatives under this Section 5.6 shall be treated as \u201cEvaluation\nMaterial\u201d for purposes of the Confidentiality Agreement (and, if and to the extent applicable, such information shall\nbe further treated as \u201cRestricted Evaluation Material\u201d for purposes of the Clean Room Agreement or \u201cRestricted\nSynergies Evaluation Material\u201d for purposes of the Synergies Clean Team Agreement). Notwithstanding any other\nprovision hereof, each Party agrees that it shall not, and shall cause its Representatives not to, prior to the Effective\nTime, use any information obtained under this Section 5.6 for any competitive or other purpose unrelated to the\nconsummation of the Merger\u037e provided, however, that, prior to the Effective Time, nothing in this Section 5.6 shall\nlimit any customary disclosures made by Parent to the Financing Sources, rating agencies, existing lenders (and\nrelated agents) or otherwise in connection with efforts or activities by Parent or the Financing Sources to obtain the\nFinancing\u037e provided, further, that the recipient of such information and other information contemplated to be\nprovided by the Company pursuant to this Section 5.6 agree to customary confidentiality arrangements, including\n\u201cclick through\u201d confidentiality agreements and confidentiality provisions.\nSection 5.7",
            "Section 3.15 Intellectual Property\u037e Software.\n(a) Section 3.15(a) of the Company Disclosure Schedule lists all Company Material Intellectual Property owned\nor purported to be owned by any Company Entity that is currently registered or subject to a pending application\nfor registration with a Governmental Authority (collectively, the \u201cCompany Registered Intellectual Property\u201d).\nExcept as has not resulted in and would not reasonably be expected to result in, individually or in the aggregate,\na Company Material Adverse Effect, a Company Entity is the sole and exclusive owner of all Company\nRegistered Intellectual Property and all other Company Material Intellectual Property (including the Company\nMaterial Intellectual Property created by employees and contractors within the scope of their employment or\nengagement by Company Entities), free and clear of any Lien thereof (except for any Permitted Lien and the\nCompany IP Agreements). All Company Registered Intellectual Property is subsisting, has not been abandoned\nor canceled and, to the Company\u2019s Knowledge related to the registrations included therein, is valid and\nenforceable in all material respects.\n(b) Except as has not resulted in and would not reasonably be expected to result in, individually or in the\naggregate, a Company Material Adverse Effect, a Company Entity owns, licenses or otherwise has and has had\nthe right to use all Intellectual Property used in the operation of the Company Entities\u2019 businesses as currently\nconducted.\n(c) There are, and since December 31, 2017, have been, no material Actions pending or, to the Company\u2019s\nKnowledge, threatened in writing (including cease and desist letters or requests for a license),\nA-20TABLE OF CONTENTS\nagainst any Company Entity alleging infringement, misappropriation or other violation of any Intellectual\nProperty of another Person or challenging the ownership, validity or enforceability of the Intellectual Property\nowned or purported to be owned by a Company Entity.\n(d)\u2003Except as has not resulted in and would not reasonably be expected to result in, individually or in the\naggregate, a Company Material Adverse Effect:\n(i)\u2003(1) the operation of the Company Entities\u2019 respective businesses, including any product or service\nmarketed, used, licensed, sold or otherwise provided by such Company Entity, as currently conducted and\nas conducted since December 31, 2017, is not infringing, misappropriating or otherwise violating, and has\nnot infringed, misappropriated or otherwise violated, any Intellectual Property of any other Person and (2)\nsince December 31, 2017, there has been no Action instituted or threatened in writing against a Company\nEntity alleging infringement, misappropriation, or violation of any such Intellectual Property or challenging\nthe ownership, validity or enforceability of any Intellectual Property of more than de minimis value\u037e\n(ii)\u2003(1) to the Company\u2019s Knowledge, no Person is infringing, misappropriating or otherwise violating any\nIntellectual Property owned or purported to be owned by or exclusively licensed to any Company Entity\nand (2) since December 31, 2017, no Company Entity has instituted or threatened in writing any Actions\nagainst any Person alleging any infringement, misappropriation or violation of any such Intellectual\nProperty or challenging the ownership, validity or enforceability of any Intellectual Property\u037e\n(iii)\u2003each Company Entity takes and has taken actions necessary to protect the confidentiality of trade\nsecrets included in the Company Material Intellectual Property and of confidential information of other\nPersons possessed by any Company Entities (exclusive of Personal Information, which shall be covered\nexclusively by Section 3.16 below), and, since December 31, 2017, there has been no loss of trade secret\nrights or confidentiality (including loss due to failure to take reasonable measures to protect\nconfidentiality) with respect thereto due to any breach of confidentiality by any Company Entity or, to the\nCompany\u2019s Knowledge, by any Person to which any such information has been provided by a Company\nEntity\u037e\n(iv)\u2003no current or former partner, director, stockholder, officer, or employee of each Company Entity owns,\nlicenses to the Company any Intellectual Property created while employed or working for any Company\nEntity, or retains any rights, title or interest in or to any Intellectual Property of more than de minimis value\nthat is owned or purported to be owned by the Company Entities\u037e\n(v)\u2003(1) each Company Entity takes and has taken material actions necessary to maintain the operation of\nall material Company Software and Company IT Assets, including by implementing reasonable disaster\nrecovery incident response plans and, as applicable, through contractual obligations requiring third-party\nproviders of such Company Software and Company IT Assets to take such actions, and (2) since\nDecember 31, 2017, there has been no material failure in, or disruptions of, the Company Software or the\nCompany IT Assets (including, for clarity, related to any third-party providers of such Company Software\nand Company IT Assets) that has not been fully remedied\u037e and\n(vi)\u2003(1) all material Company Software which is owned or purported to be owned by any Company Entity\nfunctions substantially in compliance with applicable documentation and specifications, (2) the Company\nIT Assets are sufficient for the conduct of the material business of the Company Entities, taken as a whole,\nas currently conducted, (3) no Software or other material that is distributed as \u201copen source software\u201d or\nunder a similar licensing or distribution model, including, but not limited to, the GNU General Public License\n(GPL), GNU Lesser General Public License (LGPL), Mozilla Public License (MPL) or GNU Affero General\nPublic License (AGPL) (\u201cOpen Source Software\u201d) has been incorporated into, linked or distributed with any\nCompany Software to deliver or provide a product or service of the Company or its Subsidiaries by or on\nbehalf of any Company Entity in a manner that would: (A) either currently or upon its distribution, require\nany Company Software (in whole or in part) to be licensed, sold or disclosed, (B) grant the right to make\nderivative works of any Company Software (in whole or in part) or (C) render such Company Software\nsubject to any of the licenses that govern such Open Source Software and (4) the Company Software\nowned or purported to be owned by any Company Entity does not, and, to the Company\u2019s Knowledge\n(despite reasonable\nA-21\nTABLE OF CONTENTS\nefforts to identify such items), all other Company Software does not, contain any device or feature\ndesigned to disrupt, disable, or otherwise impair the functioning of any such Software or any \u201cback door,\u201d\n\u201ctime bomb,\u201d \u201cTrojan horse,\u201d \u201cworm,\u201d \u201cdrop dead device\u201d or other code or routines that permit\nunauthorized access or use or the unauthorized disablement or erasure of such Software, Company IT\nAssets or information or other data (or all parts thereof) or other Software or IT assets of users.\n(e) No source code for any Company Software or proprietary artificial intelligence models or collections of data\nthat is owned or purported to be owned by any Company Entities and that is material to the businesses of the\nCompany Entities (i) is the subject of any right, title or interest of any other Person, (ii) has been provided,\nlicensed or granted any right, title or interest (including any present, contingent or other right, such as an\nescrow arrangement), or made available to any customer, business partner, escrow agent or other Person other\nthan employees of Company Entities and other than immaterial portions made available to contractors or other\nservice providers of a Company Entity solely for the purpose of providing services to the Company Entities, and\n(iii) no Company Entity has any duty or obligation (whether present, contingent, or otherwise) to deliver,\nlicense, or make available, any such source code or such artificial intelligence models and collections of data to\nany customer, business partner, escrow agent or other Person, in each case (i), (ii) and (iii) excluding the delivery\nor making available of data in the Ordinary Course of Business to operate managed care, health insurance or\npharmacy benefits related to the Company Entities, as applicable. The company possesses all source code for all\nCompany Software owned or purported to be owned by the Company Entities, and all other materials, to\ngenerate the object code for, and deliver, the Company Entities\u2019 products and services, and such products and\nservices comply in all material respects with their specifications.\n(f) Since December 31, 2017, the Company Entities have not provided or authorized access or rights to material\ncollections of data collected, generated or otherwise possessed by the Company Entities, whether in raw, de-\nidentified or aggregated form, to any Persons for material use beyond provisions or access in the Ordinary\nCourse of Business to operate managed care, health insurance or pharmacy benefits, as applicable."
        ]
    ]
}